Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY

touchEXPERT OPINIONS for touchONCOLOGY  Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions. The experts Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Dr Teresa Amaral, Tübingen University, Tübingen, Germany This touchPODCAST is for healthcare professionals outside of the UK only This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website:  https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma